Transferring innovations in cancer treatment to other diseases – Leopoldina Symposium on CAR-T cell therapy

März 5, 2024

CAR-T cells are considered a major innovation in cancer therapy: The T cells – i.e. the immune system’s white blood cells – of people with cancer are altered in laboratories in such a way that they can specifically identify and eliminate tumour cells. People with previously incurable blood cancer diseases have been successfully treated in this way. Now the therapy is also being used for other diseases such as auto-immune diseases, infectious diseases, and cardiac fibrosis. In an interdisciplinary Leopoldina Symposium on Monday, 8 April and Tuesday, 9 April, international experts will discuss current CAR-T cell therapy approaches for these and other, non-malignant diseases.

from Pressemitteilungen – idw – Informationsdienst Wissenschaft https://ift.tt/etBYEn7

share this recipe:

Weitere spannende Artikel

Bioreactor Allows Automated Long-Term Culturing of Stem Cells

Januar 2, 2025

Human induced pluripotent stem cells (hiPSCs) are considered as a promising tool in medicine, with the potential to unlock treatments for many health conditions such as neurodegenerative diseases and disorders. However, producing large amounts of hiPSCs remains a challenge. Researchers from the Fraunhofer Translational Center for Regenerative Therapies TLC-RT at the Fraunhofer Institute for Silicate Research ISC have now developed a bioreactor that can be used for automated long-term culturing of hiPSCs.

Bioreaktor ermöglicht automatisierte Langzeitkultivierung von Stammzellen

Januar 2, 2025

Humane induzierte pluripotente Stammzellen (hiPSCs) gelten als vielversprechendes Werkzeug in der Medizin: Künftig sollen sie die Therapie von vielen Leiden wie etwa neurodegenerativen Erkrankungen ermöglichen. Nach wie vor ist jedoch die Herstellung großer Mengen an hiPSCs eine Herausforderung. Forschende des Fraunhofer-Translationszentrums für Regenerative Therapien TLZ-RT am Fraunhofer-Institut für Silicatforschung ISC haben nun einen Bioreaktor entwickelt, mit dem eine automatisierte Langzeitkultivierung von hiPSCs gelingt.